Background -Theophylline is a well known bronchodilator which has been used for more than 50 years in the treatment of obstructive pulmonary diseases. In patients with severe chronic obstructive pulmonary disease whose cardiopulmonary performance is Theophylline continues to be widely used in the treatment of obstructive lung diseases and may improve the ventilatory capacity by its bronchodilator effect and possibly by an effect on respiratory muscle performance.'`5 Murciano et aP in a randomised controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease (COPD) found an improvement in respiratory function and dyspnoea which they related to improved respiratory muscle performance. Marsh et aP found a delay in skeletal muscle fatigue during progressive exercise at therapeutic concentrations of theophylline, suggesting an enhancement of the oxidative capacity of the muscle. The purpose of the present study was to further assess the possible effect of improved respiratory function on exercise performance in patients with COPD in a randomised, placebo controlled, double blind, crossover trial. The hypothesis was that any improvement in respiratory function would improve exercise performance in subjects limited by their ventilatory capacity.
tive pulmonary disease whose cardiopulmonary performance is limited by their ventilatory capacity the administration of theophylline may improve exercise performance. Methods -A randomised, placebo controlled, double blind, crossover trial was conducted in 22 patients with severe but stable disease. The patients (mean age 68 years) were studied before and after one month of placebo and one month of treatment with a sustained release preparation of theophylline administered orally. The theophylline dose was adjusted until a blood level above 55.5 umol/l was achieved. The two treatments were administered in random order and separated by a two week washout period. After Theophylline in COPD blood level above 55 5 gimol/l. After one month pulmonary function tests, MVV, arterial blood gas measurements, and an incremental exercise test according to the Wasserman protocol6 were performed. Pulse oximetry was recorded continuously during exercise. After a washout period of two weeks a crossover trial was performed in the same fashion as described above: those patients previously on theophylline received placebo and vice versa. After another month the tests were repeated. Precautions were taken to ensure that all patients on theophylline had blood levels above 55.5 pmol/l.
Pulmonary function tests were performed on a Jaeger Transferscreen II. MVV was performed with the patient breathing maximally into the pneumotachograph for a period of 10 seconds and multiplied to obtain a one minute value. The incremental exercise study was performed on a cardiopulmonary exercise unit which included an electronically braked cycle ergometer (Ergoline 800), a pneumotachograph and a gas analyser module (CPX Med Graphics), and a computer (Mitsubishi MP 286). Pulse oximetry was recorded continuously by an S-100 pulse oximeter (Simed). The subjects were connected to an ECG (6353 Cardiofax Nihon Kohden). After a three minute rest period the subjects performed unloaded pedalling at a cycle speed of 60 rpm. The work rate was progressively increased by 10 watts/minute in a ramp programme until the subject could no longer maintain a cycle frequency of 40 rpm. The data of the incre- The effects on arterial blood gas levels and oxygen saturation of one month of treatment with theophylline compared with placebo are shown in table 3. The mean Pao2 and Paco2 at rest, as well as oxygen saturation at rest and at maximal effort, improved significantly after the administration of theophylline compared with placebo (p < 0 05). Table 4 shows the cardiopulmonary exercise data for the placebo and theophylline periods. Work rate increased by 15 3% (p < 0 001) and, as a result, Vo2max/kg increased by 12-1% (p< 0001). Heart rate at maximal effort also increased (p<0 01), and VEmax increased by 11 2% (p<0-001). The dyspnoea index at maximal effort (VEmax/MVV) did not change.
No significant difference was found between baseline and placebo values in the pulmonary function parameters, arterial blood gas values, and cardiopulmonary exercise data.
Discussion
After one month of treatment with slow release theophylline a significant improvement in ventilatory capacity was noted which, in turn, induced a significant improvement in exercise performance. The possible mechanisms that account for these beneficial effects must be related to the pharmacological effects of the drug.
Theophylline is an established bronchodilator and is mainly used for diminishing airway Fink, Kaye, Sulkes, Gabbay, Spitzer Vereen et al '9 and is attributed to an increase in ventilation induced by the central stimulatory effect of the drug.
In conclusion, we speculate that the improvement in workload capacity and in the resultant Vo2max is related to the improvement in the ventilatory capacity as expressed by the significant increase in MVV following the administration of slow release theophylline. Whatever the mechanism, slow release theophylline in therapeutic doses may be beneficial in improving exercise tolerance in patients with severe COPD.
